Identification of RFC4 as a potential biomarker for pan‐cancer involving prognosis, tumour immune microenvironment and drugs
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18478 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Lei Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science, Inner Mongolia University, Hohhot, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Tumor Microenvironment, Gene Expression Regulation, Neoplastic, Replication Protein C. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Inner Mongolia, National Natural Science Foundation of China (CN), Natural Science Foundation of Inner Mongolia Autonomous Region.
Abstract (Originalsprache)
RFC4 is required for DNA polymerase δ and DNA polymerase ε to initiate DNA template expansion. Downregulated RFC4 inhibits tumour proliferation by causing S‐phase arrest and inhibiting mitosis, resulting in the reduction of tumour cells. RFC4 has been implicated that it plays an important role in the initiation and progression of cancers, but a comprehensive analysis of the role of RFC4 in cancer has not been performed. We comprehensively analysed the expression, prognosis, methylation level, splicing level, relationship of RFC4 and immune infiltration, and pan‐cancer immunotherapy response used various databases (including TCGA, GTEx, UALCAN, Oncosplicing, TIDE, TISCH, HPA and CAMOIP), and experimented its biological function in HCC. Through pan‐cancer analysis, we found that RFC4 is significantly upregulated in most tumours. The tumour patients with high expression of RFC4 have poor prognosis. The methylation level and variable splicing level of RFC4 were abnormal in most tumours compared with the adjacent tissues. Furthermore, RFC4 was closely associated with immune cell infiltration in various cancers. RFC4 was significantly co‐expressed with immune checkpoints and other immune‐related genes. The expression of RFC4 could indicate the immunotherapy efficacy of some tumours. The RFC4 expression was associated with sensitivity to specific small molecule drugs. Cell experiments have shown that downregulated RFC4 can inhibit cell cycle and tumour cell proliferation. We conducted a systematic pan‐cancer analysis of RFC4, and the results showed that RFC4 can serve as a biomarker for cancer diagnosis and prognosis. These findings open new perspectives for precision medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Science, Inner Mongolia University, Hohhot, China.
- School of Basic medical, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
ORCID-Profile: Lei Yu, Jia Yan, Changshan Wang
Förderung
- Natural Science Foundation of Inner Mongolia
- National Natural Science Foundation of China (CN)
- Natural Science Foundation of Inner Mongolia Autonomous Region
Zitieren
APA
Yu, L., Li, J., Zhang, M., Li, Y., Bai, J., Liu, P., Yan, J., & Wang, C. (2024). Identification of RFC4 as a potential biomarker for pan‐cancer involving prognosis, tumour immune microenvironment and drugs. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18478
Vancouver
Yu L, Li J, Zhang M, Li Y, Bai J, Liu P, et al. Identification of RFC4 as a potential biomarker for pan‐cancer involving prognosis, tumour immune microenvironment and drugs. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18478
BibTeX
@article{Yu2024,
author = {Yu, Lei and Li, Jing and Zhang, Mingyang and Li, Yu and Bai, Jing and Liu, Pengxia and Yan, Jia and Wang, Changshan},
title = {Identification of RFC4 as a potential biomarker for pan‐cancer involving prognosis, tumour immune microenvironment and drugs},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18478}
}
EUVIMED